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statistics,1 Gill Lawrence, director,2 Jem Rashbass, director,3 Franco Berrino, director,4 Bernard Rachet, senior
lecturer in cancer epidemiology1
ABSTRACT
Objectives To simulate each of two hypothesised errors in
the National Cancer Registry (recording of the date of
recurrence of cancer, instead of the date of diagnosis, for
registrations initiated from a death certificate; long term
survivors who are never notified to the registry), to
estimate their possible effect on relative survival, and to
establishwhether lower survival in the UKmight be due to
one or both of these errors.
Design Simulation study.
Setting National Cancer Registry of England and Wales.
PopulationPatients diagnosedas having breast (women),
lung, or colorectal cancer during 1995-2007 in England
and Wales, with follow-up to 31 December 2007.
Main outcome measureMean absolute percentage
change in one year and five year relative survival
associated with each simulated error.
Results To explain the differences in one year survival
after breast cancer between England and Sweden, under
the first hypothesis, date of diagnosis would have to have
been incorrectly recorded by an average of more than a
year for more than 70% of women known to be dead.
Alternatively, under the second hypothesis, failure to
register even 40% of long term survivors would explain
less than half the difference in one year survival. Results
were similar for lung and colorectal cancers.
Conclusions Even implausibly extreme levels of the
hypothesised errors in the cancer registry data could not
explain the international differences in survival observed
between the UK and other European countries.
INTRODUCTION
International disparities in survival after cancer have
repeatedly been shown between European countries
of comparable wealth and development in the EURO-
CARE studies.1-4 Survival for many cancers has often
been lower in both theUnitedKingdom andDenmark
than in other Nordic and western European countries.
The International Cancer Benchmarking Partnership
(ICBP) study of survival after cancer up to 2007 inAus-
tralia, Canada, Denmark, Norway, Sweden, and the
UK suggests that these differences in survival still
exist.5 The EUROCARE results and the data on
which they are based have been criticised, particularly
in the UK.6 Such results have nevertheless contributed
to the evidence base for the NHS cancer plan (2000)
and the cancer reform strategy (2007) in England,7 8 as
well as cancer plans inDenmark, Finland, France,Nor-
way, and Australia. A recent editorial, published while
the ICBP study was in progress, again calls inter-
national comparisons of survival into question.9
Entitled “UK cancer survival statistics are misleading
andmake survival lookworse than it is,” its subject was
a report that mortality from breast cancer fell more
rapidly in England and Wales than in other large Eur-
opean countries between 1989 and 2006.10
In their editorial,9 Beral and Peto interpreted trends
in mortality from breast cancer in Europe as incompa-
tiblewith survival after breast cancer being lower in the
UK than inother countries.4 11 The authors hypothesise
instead that the low reported survival in the UK could
arise as an artefact from two main errors. Firstly, they
propose that because registration of cancer is not stat-
utory in England and Wales, a large proportion of
cases are registered only because death certificates
mentioning cancer are routinely provided to the regis-
tries. They infer that when a registration initiated by a
death certificate is traced back to obtain clinical data
from a hospital, the registry will incorrectly record
the date of a recurrence of breast cancer shortly before
death, not the correct date of the initial diagnosis. The
true survival time for that patient would then be mis-
represented in the registry data, thus reducing the over-
all estimate of survival in the population. Secondly,
they suggest that UK survival statistics are falsely low
because some long term survivors are never registered.
This implies the existence of a substantial pool of
women who are diagnosed as having breast cancer,
are treated, and survive without any of their clinical
information reaching the cancer registry, and who
later die of something else with no mention of breast
cancer on their death certificate. We have examined
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how national estimates of survival would change if
each of these errors actually occurred.
METHODS
We used data on patients registered in the National
Cancer Registry of England and Wales in 1995-2007
with follow-up to 31 December 2007.12 In addition to
breast cancer in women (the topic of the editorial), we
analysed survival for cancers of the lung and colorec-
tum (both sexes) to assess how the effect of the errors
might vary with the lethality of the cancer.
In analysing the survival of a group of patients with
cancer, describing the survival that is related directly to
the disease is preferable to describing the observed
(crude) survival of the group of patients. This concept
is known as net survival: the survival that would occur
if mortality from other causes of death was removed.
Relative survival is the most defensible method of esti-
mating net survival in population based studies, as it
does not rely on accurate reporting of cause of
death.13 Survival is traditionally estimated for a single
cohort of patients followed through time (the cohort
approach). However, survival in the near future can
also be predicted by using probabilities of death
derived frompatientswhowere being followedupdur-
ing the most recent time period for which mortality
data are available (the period approach).14
Firstly, we estimated relative survival up to five years
after diagnosiswith themaximum likelihood approach
for individual records,15 implemented with the open
source algorithm strel.16 We used the cohort approach
for patients diagnosed as having cancer during 1995-9;
this was the period covered by EUROCARE-4,4 the
results of which were criticised in the editorial. We
used the period approach to produce short term pre-
dictions of survival for patients diagnosed as having
cancer during 2005-7, as in the International Cancer
Benchmarking Partnership study.5 Table 1 shows the
differences in one year and five year survival between
Sweden and England observed in these two studies.
We then simulated each of the hypothesised errors
and estimated the change in survival that would arise
if they occurred to varying degrees.
Cancer registrations assigned date of recurrence, instead of
date of diagnosis
This hypothesis suggests that, for a proportion of those
cancer registrations that are initiated by a death certifi-
cate and then successfully traced back to a clinical
record, the true date of diagnosis is actually much ear-
lier than the date recorded in the cancer registry, which
might instead represent the date of recurrence. To
simulate the effect on national estimates of survival of
the registered date of diagnosis beingmore recent than
it should be, we extended survival time for randomly
selected separate samples of 5%, 10%, 20%, 30%, 50%,
and 70%of deceased patients. This is an extreme range
of possible error because the proportion of such cases
ranged from 9.7% for breast cancer to 18.3% for lung
cancer in the West Midlands region during 2001-8
(table 2). We randomly selected the extensions of sur-
vival from Poisson distributions with means of 6, 12,
18, 24, 36, 48, 60, 84, and120months; thiswas again an
extreme range of possible error, because the median
survival time for women registeredwithmetastatic dis-
ease in the West Midlands during 1995-2002 was less
than ninemonths.We applied each combination of the
proportion of deceased patients affected by the error
and the simulatedmean extension of survival for those
patients iteratively to the national data and estimated
relative survival in each of 100 resulting datasets: the
survival averaged on these datasets flattened from
about the 60th replication. We show the mean and
the range of the 100 survival estimates.
In the preceding simulation, we assumed that erro-
neous recording of the date of diagnosis was equally
probable for any patient who had died. In fact, as the
error supposes that the recorded date is the date of a
recurrence, assuming that patients with a recurrence
are likely to have shorter recorded survival times is
logical.We reproduced thiswith two further sensitivity
analyses that involved changing the characteristics of
the sample of women selected. Firstly, we determined
the distribution of age at death for women who died
during 1995-9 and who had been notified to the regis-
try only because “breast cancer” was mentioned on
their death certificate. We have previously shown
that such cases have much shorter survival than do
those notified to the registry by other means.1 We
then replicated this age distribution when selecting
our samples. Within each single year of age, the
women were randomly selected. Secondly, and sepa-
rately, we selected a sample of women whose mean
survival time, as recorded in the registry, was very
short: only one tenth of that of all deceased patients.
In each of the two sensitivity analyses, we attributed
additional survival time to the sample and did a full
set of simulations as described above.
Table 1 | Absolute difference (percentage) in age standardised relative survival between
Sweden and England in published studies
Site of cancer
EUROCARE-41-4: patients
diagnosed during 1995-9
(cohort approach)
ICBP5: patients alive during 2005-7
(period approach)
One year Five years One year Five years
Colon:
9.1* 9.0*
Men 9.1 8.2
Women 10.3 7.2
Rectum:
Men 7.1 7.4
Women 7.4 8.1
Breast (women) 4.7 7.3 3.8 6.9
Lung:
13.8 7.5Men 8.4 3.1
Women 12.0 6.5
Positive values indicate that survival was higher in Sweden.
ICBP=International Cancer Benchmarking Partnership.
*Combined colorectal.
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Failure to register long term survivors (five years or more)
To simulate failure to register patients with cancer who
survived at least five years after diagnosis (long term
survivors), we duplicated the records of various propor-
tions (5%, 10%, 20%, 30%, and 40%) of randomly
selected long term survivors who had in fact been regis-
tered. For example, if 30% of long term survivors were
supposedly unknown to the registry, we duplicated 43
randomly selected long term survivors for every 100
long term survivors actually registered (100/143=70%).
Long term survivors unknown to the registry are
likely to be younger than those who are registered.
This is because to have survived for the full 13 year
period covered by the study, their mean survival
would have to be substantially greater than five years
(whereas that of registered five year survivors would
not), so unregistered long term survivors would be
expected to be younger than registered long term sur-
vivors. To reproduce this, we repeated the process by
skewing the probability of the cancer not being regis-
tered by age (skewed to the younger ages). We used a
simple approach to examine two different levels of age
skew:moderate, inwhichwe calculated the probability
of not being registered as inversely proportional to age
at diagnosis to the power of 3, and extreme (to the
power of 10). We then estimated relative survival in
100 simulated datasets, by age group, for each level
of under-registration.
RESULTS
Cancer registrations assigned date of recurrence, instead of
date of diagnosis
Simulating errors in the date of diagnosis changed the
estimates of survival, but the observed difference in
survival between England and Sweden could be
explained only if very large proportions of patients
were affected by large errors (fig 1). For example, for
women diagnosed with breast cancer in 1995-9, the
survival time of 70% of women known to be dead
would have to have been incorrectly recorded by an
average of at least one year to increase one year survi-
val after breast cancer by 4%, whereas the difference in
one year survival between Sweden and England
reported in EUROCARE-4 was 4.7% (table 1). 17 Simi-
larly, to explain the 7.3% difference in five year survi-
val between Sweden and England, 30% of women
known to be dead would have to have had their survi-
val time incorrectly shortened by an average of at least
five years (fig 2). For women diagnosed with breast
cancer in 2005-7, the difference in five year relative
survival between Sweden and England is predicted to
be 6.9% (table 1). 5 Again, this difference could only be
fully explained if the survival time of 30% of women
known to be dead had been incorrectly shortened by
an average of five years (data not shown).
The addition of a mean of seven or 10 years (84 or
120 months) of extra survival time did not result in
increases in survival greater than those seen for five
years (60 months, data not shown). Neither of the sce-
narios examined in the sensitivity analysis resulted in
larger increases in survival (data not shown).
Results were similar for colorectal and lung cancers.
To “eliminate” the differences in five year survival
between Sweden and England reported in EURO-
CARE-4 (table 1), the recorded survival time for
deceased patients in England would have to have
been incorrectly shortened by an average of four
years or more for 20% of patients who died of color-
ectal cancer and for 10% of those who died from lung
cancer (15 000 people, data not shown).
Failure to register long term survivors (five years or more)
Simulated failure to register long term survivors also
led to underestimation of relative survival, especially
at five years after diagnosis (table 3). However, even if
40% of women with breast cancer who had survived
five or more years were missing from the registry
(that is, if long term survivors known to the registry
represented only 60% of those actually living in the
population), one year survival after breast cancer
would increase by only 2.1%, less than half the differ-
ence in survival between England and Sweden
reported in EUROCARE-4 (table 1). In this most
extreme scenario, five year survival in England and
Wales would be around 7.4% higher, similar to the
level reported for Sweden in EUROCARE-4. The
most recent estimate of the difference in five year sur-
vival between Sweden and England, a period estimate
for 2005-7 (6.9%), would not be explained even by fail-
ure to register 40% of long term survivors, which
would correspond to an increase in five year survival
of 3.5% (period estimations, table 3). The difference in
five year survival for colorectal and lung cancer would
imply around 30% under-registration for colorectal
cancer and in excess of 40% under-registration for
lung cancer (data not shown).
Introducing an age bias in the simulated failure to
register long term survivors did not change the overall
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Fig 1 | Simulated increase in one year relative survival in England and Wales by percentage of
deceased patients whose survival time was extended, and mean extension of their survival:
women with breast cancer diagnosed 1995-9. Baseline estimate is relative survival estimate in
observed data before any simulated changes in survival time. Data points represent absolute
percentage change in relative survival from baseline estimate (zero). Absolute difference in
relative survival observed between age standardised survival in England and Sweden in
EUROCARE-4 (table 1) is represented by horizontal line above baseline
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effect. It did, however, affect the age specific estimates.
When we assumed the probability of long term survi-
vors being unregistered to be the same at all ages, the
addition of up to 40% of long term survivors increased
the estimated five year survival for women aged under
50 years at diagnosis by around 13%. However, only a
small increase (less than 1%) in these values occurred
when we assumed unregistered long term survivors to
be much younger (the extreme age skew). In contrast,
in women aged 50 and over the effect of failure to reg-
ister 40% of long term survivors was an 8% increase in
survival, falling to 6% if we assumed unregistered
patients to be much younger (extreme age skew).
Combining effects of both biases
Both of the proposed biases could, potentially, be pre-
sent and act together to explain the overall effect. The
combined effect would be entirely additive, because
the biases affect different people: a patient with cancer
cannot be a deceased person whose survival has been
underestimated and at the same time an unregistered
long term survivor.
Misclassification of the date of diagnosis is relevant
only for deceased patients whose date of diagnosis was
sought by the registry after receipt of a death certificate
(table 3). For breast cancer, this is around 9%. If in half
of these cases the date of diagnosis was erroneously
recorded by an average of five years, under-registra-
tion of long term survivors would have to be in excess
of 40% to explain all the UK-Sweden difference in one
year survival and in excess of 30% to explain the differ-
ence in five year survival. The same logic, applied to
the results for colorectal cancer, implies that under-
registration would need to be 20% to explain the
difference in one year survival and 10% to explain
the difference in five year survival (data not shown).
For lung cancer, which is much more lethal, almost
all the difference between Sweden and England
would be accounted for if the date of diagnosis was
erroneously recorded for half of the deceased patients
by an average of two years (data not shown).
DISCUSSION
The simulations we report show that even if extreme
proportions of registrations of breast cancer initiated
by a death certificate contained the date of recurrence
instead of the true date of diagnosis, or if selective fail-
ure to register long term survivors reached extreme
levels, these errors could not explain the difference in
survival after breast cancer between England and Swe-
den reported in the EUROCARE studies. Even con-
sidering that the two proposed errors might work
together, the errors would still need to be implausibly
extensive to explain the full difference.
If under-registration of long term survivors from
breast cancer was as extreme as 40%, and those
womenweremuchyounger than thosewhowere regis-
tered, two conclusions would follow. Firstly, the inter-
national differences in survival among older women
would be less likely to be attributable to this artefact,
because the simulated increases in survival were much
smaller for older women, whereas the differences in
survival observed in theEUROCAREstudies between
the UK and other countries were much greater among
older women. Secondly, the age profile of womenwith
breast cancer in the UK would change markedly, and
the incidence among young women would be much
higher than currently recorded. Incidence by age in
England is currently very similar to that in Sweden
(fig 3) and in most other Western countries. If under-
registration of younger breast cancer patients in Eng-
land was as extreme as would be needed to explain the
survival deficit with Sweden, the incidence of breast
cancer by age in England would have a completely
different, unique pattern (fig 3).
The BMJ editorial discussed only two of three pro-
blems with the quality of data that might lead to under-
estimation of survival: inaccurate date of diagnosis and
incomplete ascertainment of patients with cancer. The
third is completeness of the ascertainment of death in
patients with cancer in countries other than the UK.
We consider each of these in turn.
Inaccurate date of diagnosis
The likelihood that a patient’s medical history gives
rise to a cancer registration initiated by a death certifi-
cate is a function of how information is obtained and
processed by the cancer registry. In many UK regis-
tries, death certificates mentioning cancer are received
Mean error in date of diagnosis (years)
D
if
fe
re
nc
e 
in
 5
 y
ea
r 
re
la
ti
ve
 s
ur
vi
va
l (
%
)
0 1 2 3 4 5
Sweden
0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3
5% 10% 20% 30% 50% 70%
4 5
0
4
8
12
16
20
Fig 2 | Simulated increase in five year relative survival in England and Wales by percentage of
deceased patients whose survival time was extended, and mean extension of their survival:
women with breast cancer diagnosed 1995-9. Baseline estimate is relative survival estimate in
observed data before any simulated changes in survival time. Data points represent absolute
percentage change in relative survival from baseline estimate (zero). Absolute difference in
relative survival observed between age standardised survival in England and Sweden in
EUROCARE-4 (table 1) is represented by horizontal line above baseline
Table 2 | Cancer registrations initiated by death certificate,
for which date of diagnosis was actively sought by registry
staff: West Midlands, England, 2001-8
Site of cancer
No of such cases as percentage of
All cases Cases who have died
Breast (C50*) 2.2 9.7
Lung (C34*) 16.8 18.3
Colorectum(C18*,C19*, C20*) 7.5 13.9
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and added to the registry’s databasewithin aweekor so
of the date of death, whereas information on pathology
may be processed with a time lag of three months or
more, and information on the first course of treatment
may not be fully captured for up to nine months after
diagnosis. If the patient dies shortly after diagnosis and
the death certificate mentions cancer, the certificate
may reach the registry several months before the rou-
tine process of data capture is completed. When a
death certificate remains the only source of informa-
tion after a period of months, additional details then
have to be actively traced by registry staff. Only these
cases could be subject to the erroneous recording of the
date of diagnosis suggested by Beral and Peto.9
Table 2 shows the proportion of such registrations
for breast, lung, and colorectal cancer in theWestMid-
lands regions of England in 2001-8. For breast cancer,
the date of diagnosis was actively traced by the registry
in 2.2% and 1.8% of all registrations, which corre-
sponds to 9.7% and 6.8% of women with breast cancer
who had died. By contrast, to explain the difference in
one year survival between England and Sweden
observed in EUROCARE-4, 70% of all women with
breast cancer who had died would have to have been
subject to an average error of one year in the date of
diagnosis (fig 1). Among the 7-10% or so of deceased
women for whom the proposed error is actually possi-
ble, even an average error of five years in the date of
diagnosis would explain only a small proportion of the
total difference in survival. Erroneous recording of the
date of diagnosis for cancer registrations initiated by a
death certificate is thus high unlikely to play a signifi-
cant role in the international differences in survival
after breast cancer.
The results for colorectal cancer are similar but of
smaller magnitude. The conclusion is a little different
for lung cancer—the difference in survival between
Sweden and the UK would be entirely eliminated if
the date of diagnosis was erroneously recorded by an
average of two years for as many as half the deceased
lung patients. However, this is principally a result of
the difference in the disease: survival after breast can-
cer is very good, whereas survival after lung cancer is
very poor. The recorded date of diagnosis of lung can-
cer is highly unlikely to be the date of recurrence,
because late recurrence of lung cancer is rare—most
patients die within one year of diagnosis.18
The proposition becomes more implausible when
one considers the gross error that pathologists and can-
cer registry staff would have to have been making, for
thousands of patients each year, consistently over
many years, and in each of the cancer registries across
all four UK nations, to explain the longstanding survi-
val deficit between the UK and other European coun-
tries. New, primary, invasive breast cancers typically
present as a lump in the breast. They are usually treated
by surgery. Confirmation of the diagnosis of primary
cancer from pathological examination is available for
more than 90% of women. In contrast, recurrent breast
cancer often presentswith local extension ormetastatic
deposits in bone, liver, lung, or brain or more rarely in
the contralateral breast; breast tissue pathology is
examined less often. Recurrence would often prompt
palliative treatment, often without surgery to the
breast. Such a distinctive clinical picturewould be unli-
kely to lead to misclassification of recurrence as a new
primary cancer in more than rare instances. Similar
remarks apply to colorectal and lung cancers. Further-
more, this error would have to bemade only by British
pathologists and registrars.
Beral and Peto note that most of the differences in
survival arise in the first year after diagnosis and assert
that this could also be explained bymisclassification of
a recurrence as a new diagnosis.9 Even among women
diagnosed as having breast cancer during 1992-4 who
survived the first year after diagnosis, however, a 5.7%
difference in five year survival existed between West
Midlands (England) and New South Wales
(Australia).19 The difference in this conditional five
year survival between England and Sweden for
women diagnosed during 1995-9 was 6.3%.5 In other
words, a substantial deficit in survival after cancer in
the UK remains well beyond the first year after
diagnosis.
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Fig 3 | Age specific incidence rates for breast cancer (women)
in England and Sweden, with incidence by age that would be
observed in England if 20%, 30%, or 40% of putatively
unregistered long term survivors were added to data, with
“extreme” age skew (see text)
Table 3 | Absolute increase (percentage) in relative survival
resulting from addition of putative unregistered long term
survivors (≥5 years): women diagnosed as having breast
cancer in England and Wales during 1995-9
Under-
registration (%)
1995-9cohortanalysis 2005-7 period
analysis (five years*)One year Five years
5 0.2 0.8 0.4
10 0.4 1.6 0.8
20 0.9 3.4 1.7
30 1.5 5.3 2.6
40 2.1 7.4 3.5
*Addition of long term survivors (≥5 years) had no effect on estimate for
1 year survival.
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Completeness of ascertainment of patients with cancer
We have shown that the difference between Sweden
and the UK in five year survival after breast cancer
could not be explained even if UK registries had regis-
tered only 60%of all long term survivors (that is, if 40%
of long term survivorswere never registered). If under-
registration was as extreme as that, more than one in
four of all women diagnosed as having breast cancer in
the UK would be unknown to the cancer registries.
This would mean that the true incidence of breast can-
cer in the UK is actually more than 30% higher than
currently recorded, and thus at least 10%higher than in
any other European population.20
The existence of such a large pool of unregistered
long term survivors is not compatible with a large
study showing that the incidence of breast cancer in
the National Cancer Registry was very similar to that
recorded independently in primary care in 1990-6.21
As long term survivors are more likely to have been
diagnosed as having cancer at younger ages, this
would also imply that the pattern of incidence of breast
cancer by age in the UK is completely different from
that currently seen.22 One clinical audit study suggests
the opposite: namely, that unregistered patients with
breast cancer tend to be older, short term survivors,
whose inclusion in the registry would reduce the over-
all survival observed, rather than increase it.22 This is
also likely to be true for lung and colorectal cancers,
which have poorer prognosis than breast cancer.
Beral and Peto suggest that the difference in survival
between Sweden and the UK depends on the fact that
cancer registration is statutory in Sweden. This is irre-
levant: European countries with statutory, national
cancer registration have survival that is higher than
(Finland), similar to (Denmark), and lower than (Slo-
venia) survival in the UK.4
Completeness of ascertainment of death in cancer patients
Artefactual differences in survival could also arise if
information on the death of patients with cancer was
substantially incomplete in one population. To pro-
duce lower survival in the UK, this would imply that
registries elsewhere in Europe are less successful at
linking diagnoses of cancer with the death certificate
of the same patient. We have shown that the size of
this bias is small,23 and its effect is greatest for the
most lethal types of cancer, rather than for cancers
with a good prognosis such as breast cancer. It can be
important for comparisons of long term survival
(10 years or more) but less so for short and medium
term survival. Even if 5% of deaths among registered
breast cancer patients were missed, five year survival
would increase by a relatively modest 1.7%.24 The
equivalent increases would be greater for the other
sites examined owing to their greater lethality: around
4% for colorectal cancer and 5.9% for lung cancer.
Beral and Peto assert that the quality of death certifi-
cation is sufficiently robust as the basis for trends in
mortality. They do not consider contrary evidence,
either on the quality of medical certification of the
cause of death or on international differences in the
selection and coding of the underlying cause of
death,25-27 from which cause specific death rates are
constructed. By contrast, most incident cancers are
registered on the basis of histological evidence of the
primary malignancy; several complementary sources
of information are used, and quality control at the time
of cancer registration is rigorous28: extensive, quantita-
tive evidence of this exists, both in the UK and inter
nationally.20 29 Furthermore, estimation of relative sur-
vival does not require the cause of death. Unlike trends
in cancer mortality, therefore, trends in relative survi-
val are not affected by international differences or
trends in the comparability of death certification.
Possible causal explanations
Breast cancer mortality has fallen more steeply in the
UK than in Sweden because it was so much higher in
the 1980s (42 v 26 per 100 000 woman years10). The
10% increase in five year survival seen in the UK
between 1986-90 and 1996-9 represents around a 33%
decrease in lethality, consistent with the 35% drop in
mortality over a similar period.10 Contrary to the asser-
tion of Beral and Peto, therefore, the trends in the inci-
dence of, mortality from, and survival after breast
cancer in the UK are, in fact, coherent. Nevertheless,
breast cancer mortality up to 2006 in the UK was still
higher,10 and survival up to 2007 was lower,5 than in
countries such as Sweden. Good evidence from medi-
cal records (not cancer registry data) shows that this is
partly attributable to differences in stage at diagnosis
and treatment.30 Comparative data on healthcare pro-
vision are consistent with poorer outcomes after cancer
in the UK. The UK still spends a smaller proportion of
its gross national product on healthcare than do other
developed nations. TheUKhas fewer doctors,31 in par-
ticular general practitioners,32 per head of population
than in many other similarly developed countries,
which may lead to delays in diagnosis, lower usage of
radiotherapy,33 and longer waiting times.3435
Conclusions
The simulations we report here provide evidence that
the errors conjectured by Beral and Peto are not plau-
sible explanations for the deficit in survival after cancer
between the UK and many similarly developed coun-
tries. The findings support a large body of evidence
that survival after cancer in the UK is indeed lower
and that this is likely to be related to delay in diagnosis,
lower investment in healthcare, and suboptimal care.
The quality of cancer registry data should certainly
be considered when making survival comparisons.
However, purely hypothetical concerns about the
quality of data should not be used as an excuse to dis-
miss substantial and persistent differences in survival
without quantitative examination.
The question has long since ceased to be whether
such unacceptable differences in cancer survival
exist. The question is what the underlyingmechanisms
are and what can be done to improve the outcomes for
patients with cancer in the UK.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Population based survival after cancer estimated from cancer registry data is often lower in
the UK than in other equally developed nations
The extent to which these patterns are due to real differences in the treatment of cancer
patients has been debated for more than a decade
A recent BMJ editorial asserted that lower survival in the UK is due to two specific errors in the
cancer registration process
WHAT THIS STUDY ADDS
A comprehensive simulation using the entire National Cancer Registry data has shown that
neither of the errors proposed in the BMJ editorial can plausibly explain low survival after
breast cancer in England and Wales
These analyses highlight the need to examine what can be done to improve the outcomes for
patients with cancer in the UK
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